Research programme: adenosine A2B receptor antagonists - AbbVie
Alternative Names: ATL-202; ATL-264; ATL-618; ATL-801; ATL-901; ATL-906; ATL-907Latest Information Update: 18 May 2020
At a glance
- Originator Adenosine Therapeutics LLC
- Developer AbbVie; Clinical Data
- Class
- Mechanism of Action Adenosine A2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Discontinued Chronic obstructive pulmonary disease; Ocular inflammation; Retinal disorders
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in USA (Inhalation)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Non-alcoholic-fatty-liver-disease in USA